Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 08/31/10
End: 05/31/16
Due: 05/31/17
Phase: N/A
Priority: Normal
Start: 11/30/09
End: 05/31/11
Due: 05/31/12
Phase: N/A
Priority: Normal
Start: 09/17/13
End: 02/19/15
Due: 02/19/16
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia | NCT01174888 | Alison Walker | user2@example.com | None | 2010-08-31 | 2016-05-31 | 2017-05-31 | - | - | 2025-07-14 |
| Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes | NCT00997243 | Alison Walker | user2@example.com | None | 2009-11-30 | 2011-05-31 | 2012-05-31 | - | - | 2025-07-14 |
| AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia | NCT01798901 | Alison Walker | user2@example.com | None | 2013-09-17 | 2015-02-19 | 2016-02-19 | - | - | 2025-07-14 |